These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 21967505

  • 1. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis.
    Hopfer O, Nolte F, Mossner M, Komor M, Kmetsch A, Benslasfer O, Reissmann M, Nowak D, Hoelzer D, Thiel E, Hofmann WK.
    Eur J Haematol; 2012 Feb; 88(2):144-53. PubMed ID: 21967505
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aberrant promoter methylation of Dab2 gene in myelodysplastic syndrome.
    Yang Y, Zhang Q, Xu F, Chang C, Li X.
    Eur J Haematol; 2012 Dec; 89(6):469-77. PubMed ID: 23005040
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome.
    Lin J, Wang YL, Qian J, Yao DM, Zhu ZH, Qian Z, Xu WR.
    Leuk Res; 2010 Aug; 34(8):991-4. PubMed ID: 20116099
    [Abstract] [Full Text] [Related]

  • 9. [Experimental study of SHP-1 promoter methylation in myelodysplastic syndromes and its related mechanism].
    Zhang YZ, Zhao DD, Zhao WP, Zhao HF, Zhao ZG, Wang YF, Wu XX, Han XP, Da WM.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):108-12. PubMed ID: 22730659
    [Abstract] [Full Text] [Related]

  • 10. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
    Benetatos L, Dasoula A, Hatzimichael E, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL, Crook T.
    Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
    [Abstract] [Full Text] [Related]

  • 11. Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes.
    del Rey M, O'Hagan K, Dellett M, Aibar S, Colyer HA, Alonso ME, Díez-Campelo M, Armstrong RN, Sharpe DJ, Gutiérrez NC, García JL, De Las Rivas J, Mills KI, Hernández-Rivas JM.
    Leukemia; 2013 Mar; 27(3):610-8. PubMed ID: 22936014
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
    Stifter G, Heiss S, Gastl G, Tzankov A, Stauder R.
    Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
    Lin J, Yao DM, Qian J, Wang YL, Han LX, Jiang YW, Fei X, Cen JN, Chen ZX.
    Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
    [Abstract] [Full Text] [Related]

  • 19. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
    Greco M, D'Alò F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT.
    Blood Cells Mol Dis; 2010 Oct 15; 45(3):181-5. PubMed ID: 20655775
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.